Phase II Study: Radiotherapy dose increase to hypoxic NSCLC lesions
Monday, July 10, 2017 - 22:32
in Health & Medicine
Fluorine-18-fluoromisonidazole (FMISO) is a PET radiotracer that is widely used to diagnose hypoxia (insufficient oxygen supply to tissue), and non-small cell lung cancer (NSCLC) patients with FMISO uptake are known to face a poor prognosis.